UP - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Reversal of viral and epige...
    Lee, Patrick C; Klaeger, Susan; Le, Phuong M; Korthauer, Keegan; Cheng, Jingwei; Ananthapadmanabhan, Varsha; Frost, Thomas C; Stevens, Jonathan D; Wong, Alan Yl; Iorgulescu, J Bryan; Tarren, Anna Y; Chea, Vipheaviny A; Carulli, Isabel P; Lemvigh, Camilla K; Pedersen, Christina B; Gartin, Ashley K; Sarkizova, Siranush; Wright, Kyle T; Li, Letitia W; Nomburg, Jason; Li, Shuqiang; Huang, Teddy; Liu, Xiaoxi; Pomerance, Lucas; Doherty, Laura M; Apffel, Annie M; Wallace, Luke J; Rachimi, Suzanna; Felt, Kristen D; Wolff, Jacquelyn O; Witten, Elizabeth; Zhang, Wandi; Neuberg, Donna; Lane, William J; Zhang, Guanglan; Olsen, Lars R; Thakuria, Manisha; Rodig, Scott J; Clauser, Karl R; Starrett, Gabriel J; Doench, John G; Buhrlage, Sara J; Carr, Steven A; DeCaprio, James A; Wu, Catherine J; Keskin, Derin B

    The Journal of clinical investigation, 07/2022, Letnik: 132, Številka: 13
    Journal Article

    Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I-low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.